Meropenem for Lung Infections

Standard Dosing for Hospital-Acquired Pneumonia

The Infectious Diseases Society of America recommends meropenem 1 gram IV every 8 hours as empiric monotherapy for patients without high mortality risk or MRSA risk factors, providing adequate coverage for methicillin-sensitive Staphylococcus aureus (MSSA) and gram-negative pathogens 1, 2
For patients at high risk of mortality or with MRSA risk factors, the Infectious Diseases Society of America recommends combination therapy with two antipseudomonal agents plus MRSA coverage, such as meropenem 1 gram IV every 8 hours PLUS either a fluoroquinolone or an aminoglycoside, PLUS vancomycin 15 mg/kg IV every 8-12 hours or linezolid 600 mg IV every 12 hours 1, 2

The Infectious Diseases Society of America suggests considering polymyxin-meropenem combination for severe carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia, with high-dose extended-infusion meropenem (2 grams IV every 8 hours via 3-hour infusion) with polymyxin when meropenem MIC ≤32 mg/L 3
For carbapenem-resistant Enterobacteriaceae (CRE), the Infectious Diseases Society of America recommends high-dose extended-infusion meropenem-polymyxin combination therapy, with meropenem 6 grams/day (2 grams every 8 hours) via 3-hour infusion in combination regimens, showing low-certainty evidence for advantage over polymyxin monotherapy 4, 5

The Infectious Diseases Society of America notes that meropenem does NOT cover methicillin-resistant Staphylococcus aureus (MRSA), requiring addition of vancomycin or linezolid 1, 2
Patients with structural lung disease, such as bronchiectasis or cystic fibrosis, require two antipseudomonal agents due to increased risk of gram-negative infection 1, 2

For carbapenem-resistant Enterobacteriaceae (CRE) or organisms with meropenem MIC ≥8 mg/L, administer 1-2 grams IV over 3 hours (extended infusion) every 8 hours as part of combination therapy, as recommended by the Infectious Diseases Society of America 6, 7
The Infectious Diseases Society of America recommends a high-dose regimen of 2 grams IV every 8 hours via 3-hour infusion for MIC ≥16 mg/L 6
Extended infusion maximizes time above MIC, critical for beta-lactam pharmacodynamics, according to the European Society of Clinical Microbiology and Infectious Diseases 6

The Surgical Infection Society recommends meropenem as effective monotherapy for complicated intra-abdominal infections, with typical treatment duration of 5-7 days based on source control and clinical response 6
Meropenem 1 gram IV every 8 hours is an effective single-agent option for mixed necrotizing infections of skin, fascia, and muscle, as suggested by the Infectious Diseases Society of America 8
The American Academy of Pediatrics recommends meropenem as an alternative to cefotaxime or ceftriaxone for bacterial meningitis in pediatric patients ≥3 months, with equivalent clinical and microbiological outcomes 9, 10

For CRE infections, combine meropenem with a second active agent when MIC ≤8 mg/L, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 7, 6
For CRAB infections, polymyxin-meropenem combination may be considered for severe infections, though evidence shows no mortality benefit in recent trials, according to the Infectious Diseases Society of America 11, 7